GVL

GlobalVetLink and the New York State Department of Agriculture and Markets Launch Innovative Partnership to Support Animal Health and Traceability

Retrieved on: 
Thursday, February 1, 2024
Partnership, USDA, GVL, Veterinarian, Certificate, Communication, Market, Livestock, Movement

AMES, Iowa, Feb. 1, 2024 /PRNewswire/ -- The New York State Department of Agriculture and Markets and GlobalVetLink (GVL), the trusted name in digital compliance solutions for animal health, today announced a new partnership to further New York's efforts to transition to digital CVIs (Certificates of Veterinary Inspection) for enhanced traceability. Through this strategic collaboration, veterinarians in New York State will gain access to the GVL platform and create Production Animal CVIs with an origin in New York free of charge.

Key Points: 
  • Through this strategic collaboration, veterinarians in New York State will gain access to the GVL platform and create Production Animal CVIs with an origin in New York free of charge.
  • Chief Revenue Officer Aaron Avery said, "We are thrilled to be collaborating with the New York State Department of Agriculture and Markets.
  • Using the GVL Compliance Assistant platform, New York veterinarians can issue electronic CVIs that streamline workflows, save time, and improve data accuracy and availability for state animal health officials.
  • Funding to support this project was provided to the Department through USDA's Animal Disease Traceability program.

GlobalVetLink Announces Major Product Update

Retrieved on: 
Monday, January 15, 2024
Privacy, Health, VMX, GVL, Government, Fraud, Reproduction, Vaccination, Veterinary medicine, Access, Security printing

AMES, Iowa, Jan. 15, 2024 /PRNewswire/ -- GlobalVetLink (GVL), the trusted name in digital compliance solutions for animal health, has announced a sweeping set of enhancements to the GVL Compliance Assistant platform aimed at digital security. GlobalVetLink's new SmartCert technology adds verifiable digital fraud protection, automated certificate routing, and secure sharing, all built on GVL's SOC-2 secure platform.

Key Points: 
  • Revolutionary SmartCert technology adds digital authenticity, verification, and SOC-2 security to all GlobalVetLink electronic animal health compliance documents.
  • "GlobalVetLink is the only platform in digital animal health that meets state and federal security standards for digital compliance documentation," said Gary Ambrosino, CEO of GlobalVetLink.
  • Current customers, including veterinary clinics and state and federal agencies, should contact GlobalVetLink directly to enroll in the Early Access program.
  • Visit the GlobalVetLink website to learn about the new features, sign up for platform demos, or subscribe for further product update notifications.

Priothera – US FDA grants Orphan Drug Designation to mocravimod to improve the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with hematologic malignancies

Retrieved on: 
Monday, November 27, 2023
Entrepreneurship, Food, Hematopoietic stem cell transplantation, Bone marrow, FDA, Graft-versus-host disease, ODD, GVL, Orphan drug, Patient, Safety, AML, Pharmaceutical industry

Florent Gros, Co-Founder and CEO of Priothera, commented: “We are very pleased that the US FDA granted mocravimod this Orphan Drug designation.

Key Points: 
  • Florent Gros, Co-Founder and CEO of Priothera, commented: “We are very pleased that the US FDA granted mocravimod this Orphan Drug designation.
  • This designation emphasizes the importance of developing novel therapeutic options to improve the outcome and success of maintenance therapy following allo-HSCT in blood cancer patients.
  • Mocravimod, which has been previously tested in multiple autoimmune indications, is being developed to enhance the curative potential of allo-HSCT.
  • Moreover, it has shown a clinically meaningful outcome in a Phase 1b/2a study1 in patients with hematologic malignancies undergoing allo-HSCT.

GlobalVetLink Announces GVL Pet TravelPass™ for China

Retrieved on: 
Thursday, August 10, 2023
Learning, Checklist, Software as a service, Travel, Veterinarian, GVL, Movement, USDA, Dog, Pet, Regulatory affairs, Health, AMES, Cat, Veterinary medicine, Medical device

AMES, Iowa, Aug. 10, 2023 /PRNewswire/ -- GlobalVetLink, the pioneer and leader in productivity solutions for veterinary compliance, has announced that China has been added to the GVL Pet TravelPass™ as a fully supported international destination. The GVL Pet TravelPass equips veterinarians and veterinary technicians with an accurate and automatic way to create international travel documents for cats and dogs. The addition of China adds a highly requested destination to GVL's Compliance Assistant platform, already in use at over 10,000 veterinary clinics.

Key Points: 
  • "We're excited to add China to the supported countries included in the GVL Pet TravelPass for international pet travel," said Stacey Noe, GlobalVetLink Director of Product.
  • "The addition of China to the GVL Pet TravelPass for international pet travel is another way we're making animal health and movement compliance easy and accurate for our customers," said Dr. Martin Zaluski, GlobalVetLink Head of Regulatory Affairs.
  • "We're excited to help veterinarians simplify international pet travel, which can be a painstaking and nerve-racking process without the right tools such as the GVL Pet TravelPass."
  • In addition to the GVL Pet TravelPass, GlobalVetLink also provides FlyWithMyPet.com , a resource for pet owners interested in learning more about the requirements for taking their pets on an international trip.

Marty Zaluski, DVM, Joins GlobalVetLink as Head of Regulatory Affairs

Retrieved on: 
Monday, July 17, 2023
EHM, Veterinarian, Head, Trichomoniasis, GVL, Movement, Animal, Michigan State University College of Veterinary Medicine, Regulatory affairs, Health, Veterinary medicine, Brucellosis, Anthrax, DVM, Montana Department of Environmental Quality, AMES, Medical device

AMES, Iowa, July 17, 2023 /PRNewswire/ -- GlobalVetLink, the pioneer and leader in digital animal health and movement compliance, has announced the appointment of Martin Zaluski, DVM, as Head of Regulatory Affairs. With an extensive background in animal health, Dr. Zaluski brings a wealth of experience and expertise at the state and federal regulatory level to GlobalVetLink as the company continues to expand its role in automating complex regulatory compliance tasks for veterinarians. 

Key Points: 
  • Dr. Marty Zaluski has joined the animal health and movement compliance software company GlobalVetLink, where he will manage industry relations and platform compliance.
  • AMES, Iowa, July 17, 2023 /PRNewswire/ -- GlobalVetLink, the pioneer and leader in digital animal health and movement compliance, has announced the appointment of Martin Zaluski, DVM, as Head of Regulatory Affairs.
  • With an extensive background in animal health, Dr. Zaluski brings a wealth of experience and expertise at the state and federal regulatory level to GlobalVetLink as the company continues to expand its role in automating complex regulatory compliance tasks for veterinarians.
  • "I am excited to bring my experience in private and regulatory medicine, and passion for innovation to the GlobalVetLink team," said Dr. Martin Zaluski.

GlobalVetLink and Veterinary Innovative Partners Announces Partnership to Streamline Clinic Processes

Retrieved on: 
Thursday, September 15, 2022
VMD, Partner, Health, VIP, Safety, Efficiency, Trade reporting and compliance engine, Compliance, Veterinarian, USDA, Patient, Travel, GVL, Parent, PETS, Animal, Multimedia, International, Software as a service, View, Vaccine, AMES

AMES, Iowa, Sept. 15, 2022 /PRNewswire/ -- Veterinary Innovative Partners has partnered with GlobalVetLink to implement the GlobalVetLink Compliance Assistant in their veterinary hospitals. The GVL Compliance Assistant is a comprehensive SaaS platform designed to streamline animal health compliance for all veterinary practices. Adding the GlobalVetLink platform to a veterinary hospital's suite of tools allows for seamless compliance and increased efficiency for veterinarians and hospital staff.

Key Points: 
  • AMES, Iowa, Sept. 15, 2022 /PRNewswire/ -- Veterinary Innovative Partners has partnered with GlobalVetLink to implement the GlobalVetLink Compliance Assistant in their veterinary hospitals.
  • The GVL Compliance Assistant is a comprehensive SaaS platform designed to streamline animal health compliance for all veterinary practices.
  • Adding the GlobalVetLink platform to a veterinary hospital's suite of tools allows for seamless compliance and increased efficiency for veterinarians and hospital staff.
  • The GVL Compliance Assistant is a comprehensive SaaS platform designed to streamline animal health compliance for all veterinary practices.

GlobalVetLink and Heart + Paw Announces Partnership to Streamline Clinic Processes

Retrieved on: 
Thursday, September 1, 2022
Technology, Safety, GVL, View, Entrepreneurship, USDA, Parent, Veterinarian, Workflow, Multimedia, Software as a service, Animal, Compliance, International, Trade reporting and compliance engine, Industry, Health, Heart, Efficiency, Travel, Medical device, AMES

AMES, Iowa, Sept. 1, 2022 /PRNewswire/ -- Heart + Paw has partnered with GlobalVetLink to implement the GlobalVetLink Compliance Assistant in their veterinary hospitals across the Northeast. The GVL Compliance Assistant is a comprehensive SaaS platform designed to streamline animal health compliance for all veterinary practices. Adding the GlobalVetLink platform to a veterinary hospital's suite of tools allows for seamless compliance and increased efficiency for veterinarians and hospital staff.

Key Points: 
  • AMES, Iowa, Sept. 1, 2022 /PRNewswire/ -- Heart + Paw has partnered with GlobalVetLink to implement the GlobalVetLink Compliance Assistant in their veterinary hospitals across the Northeast.
  • The GVL Compliance Assistant is a comprehensive SaaS platform designed to streamline animal health compliance for all veterinary practices.
  • "Enabling our team with the GVL software was integral in our continued focus to bring innovative solutions into our Heart + Paw practices,"said Dr. George Melillo, Co-Founder and Chief Veterinary Officer at Heart + Paw.
  • "As our pet parents significantly increased the demand for travel we needed to streamline our process with GlobalVetLink.

Priothera Receives Fast Track Designation for mocravimod in Combination with Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Post Remission Therapy of Acute Myeloid Leukemia (AML) Patients

Retrieved on: 
Tuesday, May 31, 2022
FTD, HealthCap, Company, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Acute myeloid leukemia, Regulatory affairs, Hematopoietic stem cell transplantation, Modulation, HSCT, AML, Patient, GVL, Review, Lymphatic system, Adult, Mortality, Graft-versus-host disease, FDA, Safety, GVHD, Maintenance, LinkedIn, Fast Track, LLC, Entrepreneurship, CEO, Pharmaceutical industry

Karen Von Graevenitz, Head of Regulatory Affairs at Priothera, commented:"The Fast Track designation grant for mocravimod in combination with allogeneic HSCT is an important milestone and underlines the significant unmet need in AML patients undergoing HSCT, a serious disease where currently no available therapy exists.

Key Points: 
  • Karen Von Graevenitz, Head of Regulatory Affairs at Priothera, commented:"The Fast Track designation grant for mocravimod in combination with allogeneic HSCT is an important milestone and underlines the significant unmet need in AML patients undergoing HSCT, a serious disease where currently no available therapy exists.
  • This important regulatory milestone moves us a step closer to bringing mocravimod to patients with AML and other hematologic malignancies."
  • Mocravimod will be investigated as an adjunctive and maintenance treatment in a Phase 2b/3 study as a potential treatment for patients with Acute Myeloid Leukemia (AML) receiving allogeneic hematopoietic stem cell transplantation (HSCT).
  • Allogeneic HSCT is the only potentially curative approach for AML patients, but current treatments have unacceptably high mortality and morbidity rates.

Priothera Receives Fast Track Designation for mocravimod in Combination with Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Post Remission Therapy of Acute Myeloid Leukemia (AML) Patients

Retrieved on: 
Tuesday, May 31, 2022
FTD, HealthCap, Company, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Acute myeloid leukemia, Regulatory affairs, Hematopoietic stem cell transplantation, Modulation, HSCT, AML, Patient, GVL, Review, Lymphatic system, Adult, Mortality, Graft-versus-host disease, FDA, Safety, GVHD, Maintenance, LinkedIn, Fast Track, LLC, Entrepreneurship, CEO, Pharmaceutical industry

Karen Von Graevenitz, Head of Regulatory Affairs at Priothera, commented:"The Fast Track designation grant for mocravimod in combination with allogeneic HSCT is an important milestone and underlines the significant unmet need in AML patients undergoing HSCT, a serious disease where currently no available therapy exists.

Key Points: 
  • Karen Von Graevenitz, Head of Regulatory Affairs at Priothera, commented:"The Fast Track designation grant for mocravimod in combination with allogeneic HSCT is an important milestone and underlines the significant unmet need in AML patients undergoing HSCT, a serious disease where currently no available therapy exists.
  • This important regulatory milestone moves us a step closer to bringing mocravimod to patients with AML and other hematologic malignancies."
  • Mocravimod will be investigated as an adjunctive and maintenance treatment in a Phase 2b/3 study as a potential treatment for patients with Acute Myeloid Leukemia (AML) receiving allogeneic hematopoietic stem cell transplantation (HSCT).
  • Allogeneic HSCT is the only potentially curative approach for AML patients, but current treatments have unacceptably high mortality and morbidity rates.

Priothera Receives Fast Track Designation for mocravimod in Combination with Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Post Remission Therapy of Acute Myeloid Leukemia (AML) Patients

Retrieved on: 
Tuesday, May 31, 2022
FTD, HealthCap, Company, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Acute myeloid leukemia, Regulatory affairs, Hematopoietic stem cell transplantation, Modulation, HSCT, AML, Patient, GVL, Review, Lymphatic system, Adult, Mortality, Graft-versus-host disease, FDA, Safety, GVHD, Maintenance, LinkedIn, Fast Track, LLC, Entrepreneurship, CEO, Pharmaceutical industry

Karen Von Graevenitz, Head of Regulatory Affairs at Priothera, commented:"The Fast Track designation grant for mocravimod in combination with allogeneic HSCT is an important milestone and underlines the significant unmet need in AML patients undergoing HSCT, a serious disease where currently no available therapy exists.

Key Points: 
  • Karen Von Graevenitz, Head of Regulatory Affairs at Priothera, commented:"The Fast Track designation grant for mocravimod in combination with allogeneic HSCT is an important milestone and underlines the significant unmet need in AML patients undergoing HSCT, a serious disease where currently no available therapy exists.
  • This important regulatory milestone moves us a step closer to bringing mocravimod to patients with AML and other hematologic malignancies."
  • Mocravimod will be investigated as an adjunctive and maintenance treatment in a Phase 2b/3 study as a potential treatment for patients with Acute Myeloid Leukemia (AML) receiving allogeneic hematopoietic stem cell transplantation (HSCT).
  • Allogeneic HSCT is the only potentially curative approach for AML patients, but current treatments have unacceptably high mortality and morbidity rates.